2020 ASCO Highlights on HER2+ mCRC: Is Promising Trastuzumab Deruxtecan Active in Disease Refractory to Standard Therapies?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Total Health

Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.

For more info visit our website at Total Health.

2024
West Oncology APP MDONS Metro Denver Chapter Conference KU Breast Cancer Year in Review Primary Care to Oncology - Conversations for Change West Oncology Conference
2023
Evolution Conference Community Cases Tampa ASCO® Direct Philadelphia Summer Oncology Retreat Napa Valley Best of Lung Best of Hematology Community Cases Memphis Diversity, Equity, and Inclusion: Primary Care to Oncology - Conversations for Change Best of GI Best of Breast West Oncology Conference KU Breast Cancer Year in Review COEDS Discussion Series Fort Lauderdale Spring Oncology Education Retreat Oncology Nursing Society Metro Denver Chapter Conference Community Cases Atlanta SEEK Color Workshop West Oncology Updates for Advanced Practitioners and Nurses
2022
West Oncology Updates for APP & RN BioT Webinar Evolution Boston Review and Renew Sedona ASCO Direct Denver ASCO Direct Philadelphia ASCO Direct Las Vegas ASCO Direct Jacksonville ASCO Direct St. Louis Midwest Women's Cancer Conference 2022 Metro Denver Oncology Nursing Society Conference West Oncology Conference 2022 University of Kansas Cancer Center Post San Antonio Review 2022 Best of Breast Conference 2022 Diversity in Cancer Care
2021
2021 What Changes Monday Morning? Post SABCS 2021 Virtual ESMO Review OneOncology Webinars 2021 West Oncology Virtual Conference - Updates for Advanced Practitioners and Nurses 2021 Virtual Evolution: A Conference for Women by Women Optimizing HER2 Breast Cancer Webinars Extended Endocrine Therapy for HR+ BC | A Review of ASCO21 & National Practice Guidelines Post ASCO 2021 WCMM? Live Q&A Panels CML Webinars 2021 Virtual South Florida Neuroscience Symposium 2021 Open Mic May 2021 Metro Denver Oncology Nursing Society Conference Virtual West Oncology Conference 2021 Virtual Evolution Kansas City University of Kansas Cancer Center Post San Antonio Review 2021 Virtual Best of Breast inspirED Interviews
2021 ASCO Virtual Direct™ Highlights
Denver St. Louis Jacksonville Philadelphia San Francisco
2020
2020 Virtual ESMO Review 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology ctDNA and MRD Testing: Emerging Technologies and Clinical Case Applications Virtual Evolution: A Conference for Women by Women Virtual Diversity in Cancer Care Updates in Breast Cancer from San Antonio 2020 Best of Breast
2020 ASCO Virtual Direct™ Highlights
Boston St. Louis Jacksonville Philadelphia Denver San Francisco Las Vegas San Juan
Videos
COVID-19
Events

Playback speed

10 seconds

2020 ASCO Highlights on HER2+ mCRC: Is Promising Trastuzumab Deruxtecan Active in Disease Refractory to Standard Therapies?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Shikha Jain

137 views

July 16, 2020

Comments 0

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

St. Louis